Skip Navigation
Megan McArdle

Megan McArdle - Megan McArdle is a senior editor for The Atlantic who writes about business and economics. She has worked at three start-ups, a consulting firm, an investment bank, a disaster recovery firm at Ground Zero, and The Economist. She is currently on leave.
More

Megan was born and raised on the Upper West Side of Manhattan, and yes, she does enjoy her lattes, as well as the occasional extra-dry skim-milk cappuccino. Her checkered work history includes three start-ups, four years as a technology project manager for a boutique consulting firm, a summer as an associate at an investment bank, and a year spent as sort of an executive copy girl for one of the disaster-recovery firms at Ground Zero � all before the age of 30.

While working at Ground Zero, Megan started Live From the WTC, a blog focused on economics, business, and cooking. She may or may not have been the first major economics blogger, depending on whether we are allowed to throw outlying variables such as Brad Delong out of the set. From there it was but a few steps down the slippery slope to freelance journalism. She has worked in various capacities for The Economist, where she wrote about economics and oversaw the founding of Free Exchange, the magazine's economics blog. She has also maintained her own blog, Asymmetrical Information, which moved to The Atlantic, along with its owner, in August 2007.

Megan holds a bachelor's degree in English literature from the University of Pennsylvania and an M.B.A. from the University of Chicago. After a lifetime as a New Yorker, she now resides in northwest Washington, D.C., where she is still trying to figure out what one does with an apartment larger than 400 square feet.

Drug Wars

By Megan McArdle
Jul 31 2009, 1:11 PM ET Comment

I'm supposed to be on holiday.  But everyone is linking to this post by Ben Domenech which, like, totally proves that I don't know what I'm talking about regarding pharma research, so I should probably point to this post by Derek Lowe, pharma researcher, which questions Ben Domenech's analysis.  It's true that I oversimplified both pharma and academia's role:  academia sometimes develops drugs, while pharma does basic research.  Such is blogging.  The broad point is that basic research and developing a working drug are two different activities, and neither is "real" innovation.  I don't want to stop government from funding basic research, and never said I did.  But producing drugs does not seem to be the government's core competence.


The broad point is that basic research and developing a working drug are two different activities, and neither is "real" innovation.  I don't want to stop government from funding basic research, and never said I did.  But producing drugs does not seem to be the government's core competence.

Presented by

More at The Atlantic

Watch and Buy: Kickstarter Is the Hipster Home Shopping Network Kickstarter Is the Hipster Home Shopping Network
Meet the 'Fly Boys' of Memphis, the Future of American Education Meet the 'Fly Boys' of Memphis, the Future of Education
How the Global Middle Class Can Save the American Middle Class How the Global Middle Class Can Save America's Middle Class
The $630-Million Trees That Sparked a Social Media Revolt in China The $630-Million Trees That Sparked an Online Revolt
Does the Supreme Court Believe in Double Jeopardy Protections? Does the Supreme Court Believe in Double Jeopardy Protections?

Join the Discussion

After you comment, click Post. If you’re not already logged in you will be asked to log in or register.
blog comments powered by Disqus
View All Correspondents

The Biggest Story in Photos

Where in the World? Part 3: A Google Earth Puzzle

May 25, 2012

Subscribe Now

SAVE 59%! 10 issues JUST $2.45 PER COPY

Facebook

Newsletters

Sign up to receive our free newsletters

(sample)

(sample)

(sample)

(sample)

(sample)

(sample)

Megan McArdle
from the Magazine

Why You Can’t Get a Taxi

And how an upstart company may change that

Europe’s Real Crisis

The Continent’s problems are as much demographic as financial. They won’t go away soon.

Why Companies Fail

GM’s stock price has sunk by a third since its IPO. Why is corporate turnaround so difficult…